{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T16:41:13Z","timestamp":1790959273553,"version":"4.1.0"},"reference-count":43,"publisher":"Public Library of Science (PLoS)","issue":"5","license":[{"start":{"date-parts":[[2024,5,29]],"date-time":"2024-05-29T00:00:00Z","timestamp":1716940800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:sec id=\"sec001\">\n<jats:title>Background<\/jats:title>\n<jats:p>Familial Pancreatic Cancer (FPC) presents a notable risk, with 3\u201310% of pancreatic adenocarcinoma cases having a family history. Studies link FPC to syndromes like HBOC, suggesting BRCA1\/BRCA2 mutations play a role. BRCA gene functions in DNA repair impact FPC management, influencing sensitivity to therapies like PARP inhibitors. Identifying mutations not only aids FPC treatment but also reveals broader cancer risks. However, challenges persist in selectively applying genetic testing due to cost constraints. This Systematic Review focuses on BRCA1\/BRCA2 significance in FPC, diagnostic criteria, prognostic value, and limitations.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec002\">\n<jats:title>Method<\/jats:title>\n<jats:p>Original articles published from 2013 to January 2023 were sourced from databases such as Scopus, PubMed, ProQuest, and ScienceDirect. Inclusion criteria comprised observational cohort or diagnostic studies related to the role of BRCA1\/2 mutation in correlation to familial pancreatic cancer (FPC), while article reviews, narrative reviews, and non-relevant content were excluded. The assessment of bias used ROBINS-I, and the results were organized using PICOS criteria in a Google spreadsheet table. The systematic review adhered to the PRISMA 2020 checklist.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec003\">\n<jats:title>Result<\/jats:title>\n<jats:p>We analyzed 9 diagnostic studies encompassing 1325 families and 4267 patients from Italy, USA, and Poland. Despite the limitation of limited homogenous PICO studies, our findings effectively present evidence. BRCA1\/2 demonstrates benefits in detecting first-degree relatives FPC involvement with 2.26\u201310 times higher risk. These mutation findings also play an important role since with the BRCA1\/2 targeted therapy, Poly-ADP Ribose Polymerase inhibitors (PARP) may give better outcomes of FPC treatment. Analysis of BRCA1 and BRCA2 administration\u2019s impact on odds ratio (OR) based on six and five studies respectively. BRCA1 exhibited non-significant effects (OR = 1.26, P = 0.51), while BRCA2 showed significance (OR = 1.68, P = 0.04). No heterogeneity observed, indicating consistent results. Further research on BRCA1 is warranted.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec004\">\n<jats:title>Conclusion<\/jats:title>\n<jats:p>Detecting the BRCA1\/2 mutation gene offers numerous advantages, particularly in its correlation with FPC. For diagnostic and prognostic purposes, testing is strongly recommended for first-degree relatives, who face a significantly higher risk (2.26\u201310 times) of being affected. Additionally, FPC patients with identified BRCA1\/2 mutations exhibit a more favorable prognosis compared to the non-mutated population. This is attributed to the availability of targeted BRCA1\/2 therapy, which maximizes treatment outcomes.<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pone.0299276","type":"journal-article","created":{"date-parts":[[2024,5,29]],"date-time":"2024-05-29T17:35:46Z","timestamp":1717004146000},"page":"e0299276","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":4,"title":["The role of germline BRCA1 &amp; BRCA2 mutations in familial pancreatic cancer: A systematic review and meta-analysis"],"prefix":"10.1371","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8476-2971","authenticated-orcid":true,"given":"Edward Kurnia Setiawan","family":"Limijadi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muflihatul","family":"Muniroh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan Wisnu","family":"Prajoko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3821-8446","authenticated-orcid":true,"given":"Kevin Christian","family":"Tjandra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-7725-8263","authenticated-orcid":true,"given":"Danendra Rakha Putra","family":"Respati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2024,5,29]]},"reference":[{"issue":"2","key":"pone.0299276.ref001","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/s10689-008-9214-8","article-title":"Family history is a significant risk factor for pancreatic cancer: results from a systematic review and meta-analysis.","volume":"8","author":"J Permuth-Wey","year":"2009","journal-title":"Fam Cancer"},{"issue":"5","key":"pone.0299276.ref002","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1053\/j.seminoncol.2016.09.002","article-title":"Familial pancreatic cancer","volume":"43","author":"GM Petersen","year":"2016","journal-title":"Semin Oncol"},{"issue":"5","key":"pone.0299276.ref003","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1158\/1055-9965.EPI-12-0195","article-title":"Risk of Pancreatic Cancer in Breast Cancer Families from the Breast Cancer Family Registry.","volume":"22","author":"E Mocci","year":"2013","journal-title":"Cancer Epidemiology, Biomarkers & Prevention."},{"issue":"16","key":"pone.0299276.ref004","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1001\/jama.2009.1529","article-title":"Risk of Pancreatic Cancer in Families With Lynch Syndrome","volume":"302","author":"F. Kastrinos","year":"2009","journal-title":"JAMA"},{"issue":"6","key":"pone.0299276.ref005","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1002\/1097-0215(20000915)87:6<809::AID-IJC8>3.0.CO;2-U","article-title":"Risk of developing pancreatic cancer in families with familial atypical multiple mole melanoma associated with a specific 19 deletion of p16 (p16-Leiden).","volume":"87","author":"HF Vasen","year":"2000","journal-title":"Int J Cancer"},{"issue":"11","key":"pone.0299276.ref006","doi-asserted-by":"crossref","first-page":"896","DOI":"10.7326\/0003-4819-128-11-199806010-00004","article-title":"Increased Risk for Cancer in Patients with the Peutz-Jeghers Syndrome","volume":"128","author":"LA Boardman","year":"1998","journal-title":"Ann Intern Med"},{"issue":"5","key":"pone.0299276.ref007","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1245\/s10434-015-5026-x","article-title":"Statewide Retrospective Review of Familial Pancreatic Cancer in Delaware, and Frequency of Genetic Mutations in Pancreatic Cancer Kindreds","volume":"23","author":"ZAK Catts","year":"2016","journal-title":"Ann Surg Oncol"},{"issue":"9","key":"pone.0299276.ref008","doi-asserted-by":"crossref","first-page":"934","DOI":"10.4161\/cbt.4.9.2141","article-title":"BRCA2-deficient CAPAN-1 cells are extremely sensitive to the inhibition of poly (ADP-ribose) polymerase: An issue of potency.","volume":"4","author":"N McCabe","year":"2005","journal-title":"Cancer Biol Ther"},{"issue":"7182","key":"pone.0299276.ref009","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1038\/nature06548","article-title":"Resistance to therapy caused by intragenic deletion in BRCA2","volume":"451","author":"SL Edwards","year":"2008","journal-title":"Nature"},{"issue":"10","key":"pone.0299276.ref010","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1634\/theoncologist.2011-0185","article-title":"An Emerging Entity: Pancreatic Adenocarcinoma Associated with a Known BRCA Mutation: Clinical Descriptors, Treatment Implications, and Future Directions.","volume":"16","author":"MA Lowery","year":"2011","journal-title":"Oncologist"},{"issue":"6","key":"pone.0299276.ref011","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1158\/1078-0432.CCR-17-3099","article-title":"Evaluating Mismatch Repair Deficiency in Pancreatic Adenocarcinoma: Challenges and Recommendations","volume":"24","author":"ZI Hu","year":"2018","journal-title":"Clinical Cancer Research"},{"issue":"5","key":"pone.0299276.ref012","doi-asserted-by":"crossref","first-page":"a001974","DOI":"10.1101\/mcs.a001974","article-title":"Successful immune checkpoint blockade in a patient with advanced stage microsatellite-unstable biliary tract cancer","volume":"3","author":"E Czink","year":"2017","journal-title":"Molecular Case Studies"},{"issue":"2","key":"pone.0299276.ref013","doi-asserted-by":"crossref","first-page":"193","DOI":"10.3390\/cancers11020193","article-title":"Hereditary Pancreatic Cancer: A Retrospective Single-Center Study of 5143 Italian Families with History of BRCA-Related Malignancies.","volume":"11","author":"A Toss","year":"2019","journal-title":"Cancers (Basel)."},{"issue":"18","key":"pone.0299276.ref014","doi-asserted-by":"crossref","first-page":"4447","DOI":"10.3390\/cancers14184447","article-title":"Clinical Significance of Germline Pathogenic Variants among 51 Cancer Predisposition Genes in an Unselected Cohort of Italian Pancreatic Cancer Patients.","volume":"14","author":"A Puccini","year":"2022","journal-title":"Cancers (Basel)."},{"key":"pone.0299276.ref015","doi-asserted-by":"crossref","first-page":"430","DOI":"10.4143\/crt.2016.217","article-title":"The prevalence of founder mutations among individuals from families with familial pancreatic cancer syndrome","volume":"49.2","author":"Marcin R. Lener","year":"2017","journal-title":"Cancer Research and Treatment: Official Journal of Korean Cancer Association"},{"issue":"2","key":"pone.0299276.ref016","doi-asserted-by":"crossref","first-page":"321","DOI":"10.3390\/genes13020321","article-title":"Pancreatic Cancer with Mutation in BRCA1\/2, MLH1, and APC Genes: Phenotype Correlation and Detection of a Novel Germline BRCA2 Mutation.","volume":"13","author":"MT Vietri","year":"2022","journal-title":"Genes (Basel)."},{"issue":"23","key":"pone.0299276.ref017","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1001\/jama.2018.6228","article-title":"Association Between Inherited Germline Mutations in Cancer Predisposition Genes and Risk of Pancreatic Cancer","volume":"319","author":"C Hu","year":"2018","journal-title":"JAMA"},{"key":"pone.0299276.ref018","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1038\/gim.2014.153","article-title":"BRCA1, BRCA2, PALB2, and CDKN2A mutations in familial pancreatic cancer: a PACGENE study","volume":"17.7","author":"David B. Zhen","year":"2015","journal-title":"Genetics in Medicine"},{"issue":"45","key":"pone.0299276.ref019","doi-asserted-by":"crossref","first-page":"74227","DOI":"10.18632\/oncotarget.12490","article-title":"Germline mutations in Japanese familial pancreatic cancer patients","volume":"7","author":"E Takai","year":"2016","journal-title":"Oncotarget"},{"issue":"1","key":"pone.0299276.ref020","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1038\/gim.2017.85","article-title":"Prevalence of germ-line mutations in cancer genes among pancreatic cancer patients with a positive family history","volume":"20","author":"KG Chaffee","year":"2018","journal-title":"Genetics in Medicine"},{"issue":"1","key":"pone.0299276.ref021","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/sj.bjc.6603535","article-title":"Cancer risks among BRCA1 and BRCA2 mutation carriers","volume":"96","author":"E Levy-Lahad","year":"2007","journal-title":"Br J Cancer"},{"issue":"18","key":"pone.0299276.ref022","first-page":"1365","article-title":"Cancer Risk Estimates for BRCA1 Mutation Carriers Identified in a Risk Evaluation Program.","volume":"94","author":"MS Brose","year":"2002","journal-title":"CancerSpectrum Knowledge Environment."},{"issue":"2","key":"pone.0299276.ref023","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1001\/jama.296.2.185","article-title":"Salpingo-oophorectomy and the Risk of Ovarian, Fallopian Tube, and Peritoneal Cancers in Women With a BRCA1 or BRCA2 Mutation.","volume":"296","author":"A Finch","year":"2006","journal-title":"JAMA"},{"issue":"1","key":"pone.0299276.ref024","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.eururo.2019.08.025","article-title":"Prostate Cancer Risks for Male BRCA1 and BRCA2 Mutation Carriers: A Prospective Cohort Study.","volume":"77","author":"T Nyberg","year":"2020","journal-title":"Eur Urol."},{"issue":"8","key":"pone.0299276.ref025","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1002\/pros.23795","article-title":"The association of BRCA1 and BRCA2 mutations with prostate cancer risk, frequency, and mortality: A meta\u2010analysis","volume":"79","author":"M Oh","year":"2019","journal-title":"Prostate"},{"issue":"5","key":"pone.0299276.ref026","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1002\/humu.23406","article-title":"Mutational spectrum in a worldwide study of 29,700 families with BRCA1 or BRCA2 mutations","volume":"39","author":"TR Rebbeck","year":"2018","journal-title":"Hum Mutat"},{"issue":"8","key":"pone.0299276.ref027","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1038\/nrgastro.2012.111","article-title":"Familial pancreatic cancer\u2014current knowledge.","volume":"9","author":"DK Bartsch","year":"2012","journal-title":"Nat Rev Gastroenterol Hepatol."},{"issue":"30","key":"pone.0299276.ref028","doi-asserted-by":"crossref","first-page":"3382","DOI":"10.1200\/JCO.2017.72.3502","article-title":"Deleterious Germline Mutations in Patients With Apparently Sporadic Pancreatic Adenocarcinoma","volume":"35","author":"K Shindo","year":"2017","journal-title":"Journal of Clinical Oncology"},{"issue":"1","key":"pone.0299276.ref029","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/ng0597-17","article-title":"Germline BRCA2 6174delT mutations in Ashkenazi Jewish pancreatic cancer patients","volume":"16","author":"H \u00d6zcelik","year":"1997","journal-title":"Nat Genet"},{"issue":"3","key":"pone.0299276.ref030","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1200\/JCO.2008.18.5546","article-title":"BRCA Germline Mutations in Jewish Patients With Pancreatic Adenocarcinoma","volume":"27","author":"CR Ferrone","year":"2009","journal-title":"Journal of Clinical Oncology"},{"issue":"2","key":"pone.0299276.ref031","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1158\/2159-8290.CD-15-0402","article-title":"Whole Genome Sequencing Defines the Genetic Heterogeneity of Familial Pancreatic Cancer.","volume":"6","author":"NJ Roberts","year":"2016","journal-title":"Cancer Discov"},{"issue":"17","key":"pone.0299276.ref032","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.3748\/wjg.v27.i17.1943","article-title":"BRCA mutated pancreatic cancer: A change is coming","volume":"27","author":"MN Rosen","year":"2021","journal-title":"World J Gastroenterol"},{"issue":"5","key":"pone.0299276.ref033","doi-asserted-by":"crossref","DOI":"10.1186\/bcr3020","article-title":"Genomic and phenotypic analysis of BRCA2mutated breast cancers reveals co-occurring changes linked to progression","volume":"13","author":"OA Stefansson","year":"2011","journal-title":"Breast Cancer Research"},{"key":"pone.0299276.ref034","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.humpath.2017.10.032","article-title":"BRCA1 and BRCA2 expression patterns and prognostic significance in digestive system cancers.","volume":"71","author":"GH Wang","year":"2018","journal-title":"Hum Pathol."},{"issue":"6","key":"pone.0299276.ref035","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1038\/bjc.2017.19","article-title":"Overall survival and clinical characteristics of BRCA mutation carriers with stage I\/II pancreatic cancer","volume":"116","author":"T Golan","year":"2017","journal-title":"Br J Cancer"},{"key":"pone.0299276.ref036","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2022\/5830475","article-title":"A Systematic Review and Meta-Analysis on the Prognostic Value of BRCA Mutations, Homologous Recombination Gene Mutations, and Homologous Recombination Deficiencies in Cancer.","volume":"2022","author":"C Shao","year":"2022","journal-title":"J Oncol."},{"issue":"11","key":"pone.0299276.ref037","doi-asserted-by":"crossref","first-page":"e2345013","DOI":"10.1001\/jamanetworkopen.2023.45013","article-title":"Analysis of BRCA1\u2014and BRCA2 -Related Pancreatic Cancer and Survival.","volume":"6","author":"B Boursi","year":"2023","journal-title":"JAMA Netw Open"},{"issue":"13","key":"pone.0299276.ref038","doi-asserted-by":"crossref","first-page":"3239","DOI":"10.1158\/1078-0432.CCR-20-0418","article-title":"Genomic Methods Identify Homologous Recombination Deficiency in Pancreas Adenocarcinoma and Optimize Treatment Selection","volume":"26","author":"W Park","year":"2020","journal-title":"Clinical Cancer Research"},{"key":"pone.0299276.ref039","doi-asserted-by":"crossref","first-page":"175883592210830","DOI":"10.1177\/17588359221083050","article-title":"Platinum-based chemotherapy for pancreatic cancer: impact of mutations in the homologous recombination repair and Fanconi anemia genes.","volume":"14","author":"M Emelyanova","year":"2022","journal-title":"Ther Adv Med Oncol"},{"key":"pone.0299276.ref040","doi-asserted-by":"crossref","first-page":"463","DOI":"10.5732\/cjc.011.10111","article-title":"PARP inhibitors: its role in treatment of cancer.","author":"A. Chen","year":"2011","journal-title":"Chin J Cancer"},{"issue":"23","key":"pone.0299276.ref041","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1200\/JCO.2013.53.6995","article-title":"Second-Line Oxaliplatin, Folinic Acid, and Fluorouracil Versus Folinic Acid and Fluorouracil Alone for Gemcitabine-Refractory Pancreatic Cancer: Outcomes From the CONKO-003 Trial.","volume":"32","author":"H Oettle","year":"2014","journal-title":"Journal of Clinical Oncology."},{"issue":"9","key":"pone.0299276.ref042","doi-asserted-by":"crossref","first-page":"2728","DOI":"10.1158\/1078-0432.CCR-06-3039","article-title":"ABT-888, an Orally Active Poly(ADP-Ribose) Polymerase Inhibitor that Potentiates DNA-Damaging Agents in Preclinical Tumor Models.","volume":"13","author":"CK Donawho","year":"2007","journal-title":"Clinical Cancer Research"},{"issue":"3","key":"pone.0299276.ref043","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1158\/1078-0432.CCR-1144-3","article-title":"Novel Poly(ADP-ribose) Polymerase-1 Inhibitor, AG14361, Restores Sensitivity to Temozolomide in Mismatch Repair-Deficient Cells.","volume":"10","author":"NJ Curtin","year":"2004","journal-title":"Clinical Cancer Research"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0299276","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,29]],"date-time":"2024-05-29T17:36:05Z","timestamp":1717004165000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0299276"}},"subtitle":[],"editor":[{"given":"Alvaro","family":"Galli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2024,5,29]]},"references-count":43,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2024,5,29]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0299276","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,29]]}}}